13 dec: SAS vil hente yderligere besparelser for 700 mio. svenske kr.
13 dec: Aktier/tendens: Mærsk og SAS kan tage rampelyset
13-12-2016 08:15:28

Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics

Relateret indhold
15 mar - 
Onsdagens aktier: DSV og Mærsk til tops samt bundrekord..
15 mar - 
Zealand FY: Leverer igen røde tal - men lidt bedre end ..
15 mar - 
Aktier/middag: Banker kravler op i ellers let vigende C..
Relateret debat
26 apr - 
Ja det kan jeg, modsat dig...... Den spekulative del er..
26 apr - 
Nå der var du, vi blev helt urolige for dig Alpe ;)
26 apr - 
Soliqua 929 - Victoza 30.000+ - gæt en gåde ?!

Press Release - No. 7 / 2016

 

Zealand initiates Phase IIa

clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics

             

  • An automated delivery system with both insulin and glucagon holds potential to become a paradigm shift in the treatment of type 1 diabetes

     

  • In December, Zealand initiated two Phase IIa trials, to test dasiglucagon's potential in a dual-hormone artificial pancreas system

     

  • Results from both trials are expected in H1 2017

Copenhagen, 13 December 2016 - Zealand Pharma (Zealand) today announced that it has dosed the first patients in its Phase IIa clinical trial with dasiglucagon[1] in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics. Dasiglucagon is a Zealand-invented glucagon analogue with a unique stability profile in liquid formulation. The multiple-dose version of dasiglucagon is intended for use in a dual-hormone artificial pancreas system to better control hypoglycaemia and, potentially, hereby provide insulin treated diabetes patients with options for easier and more effective management of their disease.

The Phase IIa trial is the fourth Phase II trial initiated by Zealand this year, demonstrating the significant progress in Zealand's pipeline of proprietary product candidates.

People with type 1 diabetes depends on a complex daily insulin regimen to control their blood glucose. They must regularly track and adjust their blood sugar levels to reduce the acute and chronic risks associated with hypo- and hyperglycaemia. A dual-hormone artificial (or bionic) pancreas system, which automatically delivers insulin and glucagon, aims to mimic the function of a healthy pancreas[2]

Steven J. Russell, MD, Massachusetts General Hospital Diabetes Center in Boston, MA, USA, and Principal Investigator:

"Our previous studies have shown that a dual-hormonal bionic pancreas can provide very effective management of glycemia in people with type 1 diabetes. All of our previous studies have used glucagon that have very limited stability, so the glucagon pump had to be refilled daily. More importantly, the unstable glucagon formulations will not meet the regulatory requirements to be approved for use in a bionic pancreas. This Phase IIa study will test the effectiveness of the stable glucagon analogue dasiglucagon in the dual-hormone bionic pancreas, comparing it with the unstable glucagon formulation that we have used in all of our previous studies. Demonstrating the effectiveness of a stable glucagon formulation or analogue, such as dasiglucagon, is an essential step towards making a dual-hormone bionic pancreas available to patients."

Adam Steensberg, Senior Vice President, Chief Medical & Development Officer, Zealand:

"We are happy to have initiated our fourth Phase II trial this year, showing significant progress in our clinical pipeline of medicines that we fully own and develop ourselves. This is the first trial evaluating Zealand's glucagon analogue, dasiglucagon, in the clinic for use in the dual-hormone artificial pancreas, under development by Beta Bionics and Boston University. Such a system has the ultimate potential to offer people with diabetes on insulin therapy more efficacious, safer and easier blood sugar control."

Zealand entered into a collaboration with Beta Bionics, a Boston-based company, earlier this year. Beta Bionics is developing a dual-hormone artificial (bionic) pancreas system based on advanced technology that was conceived and refined at Boston University and has been undergoing clinical trials for nearly 10 years at the Massachusetts General Hospital and, more recently, Stanford University, the University of North Carolina and the University of Massachusetts. The technology is being integrated at Beta Bionics into a pocket-sized wearable medical device called the iLetTM.

The Phase IIa trials

The aim of the Phase IIa clinical trial with Beta Bionics is to assess, for the first time, the safety, efficacy and tolerability of dasiglucagon as part of the Beta Bionics dual-hormone artificial (bionic) pancreas system in adult patients with type 1 diabetes, compared to a recombinant market glucagon. In collaboration with Beta Bionics and Boston University, the trial is conducted at the Massachusetts General Hospital Diabetes Research Center in Boston, MA, USA, with MD Steven J. Russell as Principal Investigator.

Earlier this month, Zealand initiated another Phase IIa trial with the aim of assessing PK and PD responses after administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. The first patients have been dosed.

The Phase IIa trials are designed to provide the foundation for longer clinical trials with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system. Results from both trials are expected in H1 2017.

For further information on the Phase IIa trials, see:

ClinicalTrials.gov Identifier: NCT02916251

ClinicalTrials.gov Identifier: NCT02971228

*****

For further information, please contact

Adam Steensberg,

Senior Vice President,

Chief Medical and Development Officer

Tel.: +45 50 60 36 01

, e-mail: ast@zealandpharma.com

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, e-mail:

mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates that primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe). 

Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (phase II); glepaglutide* (ZP1848) for short bowel syndrome (phase II); dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in phase II); and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).


1 Dasiglucagon is a proposed International Nonproprietary Name (pINN)

[2]

Russel et al. "Outpatient glycemic control with a bionic pancreas in Type 1 diabetes", New England Journal of Medicine (2014) 

07-16_1213 Zealand initiates Phase IIa trial with dasiglucagon


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 774914.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 apr
ZEAL
Den kommer her Jacob - og da ganske interessant læsning! Zealand-chef løfter sløret for markedsføri..
12
25 apr
ZEAL
Herunder artiklen i sit fulde omfang: Indkøbskæmper holder Sanofis forspring til Novo i kort snor Me..
12
26 apr
ZEAL
Absolut gerne!   Vh.   Zealand Pharma lægger i ovnen til USA-ekspansion Medicinal & Biotek: Toplede..
8
26 apr
ZEAL
Sikke agressiv du er, MENA - pas nu på blodtrykket...    
4
26 apr
ZEAL
Jeps - gerne! Zealand Pharma lægger i ovnen til USA-ekspansion Medicinal & Biotek: Topledelsen i Ze..
4
25 apr
ZEAL
Med de seneste oplysninger, der bekræfter de sidste 12 måneders justering af salgsestimaterne for So..
3
25 apr
ZEAL
    MedWatch mener kun at Sanofi har 1000 recepter på Soliqua. Interessant at vide hvor journalisten..
3
26 apr
ZEAL
Mit blodtryk har det fint, jeg har ikke penge i skod aktier
2
26 apr
ZEAL
Ja der skal sgu investeres og jubles over de 1000 recepter, det bliver sgu en bioporto om igen
2
26 apr
ZEAL
Det var da en veldokumenteret og grundig analyse, du her fremkommer med, hr Baron men, husk lige til..
2

Shipping: Baltic Dry-indekset falder 0,6 pct. til 1147 point

26-04-2017 14:05:11
Tørlastindekset Baltic Dry falder onsdag for syvende børsdag på stribe - denne gang med 0,6 pct. til 1147 point. Det fremgår af data fra Bloomberg News.Baltic Dry-indekset udarbejdes af London-baserede Baltic Exchange og dækker priserne for at få fragtet last som kul, korn og jernmalm. Indekset er baseret på en daglig rundspørge til mæglere over hele verden.Baltic Dry ramte et foreløbigt højdepunk..

Express Scripts lider efter afsked med megakunde - citat

26-04-2017 09:10:44
Express Scripts, der er USA's største indkøber af medicin, er havnet i en krise, efter at selskabet mistede sin største kunde, sundhedsforsikringsselskabet Anthem. Forsikringsselskabet har hidtil bidraget med 17,1 mia. dollar til Express Scripts toplinje (på cirka 100 mia. dollar i 2016, red.).Det skriver the Wall Street Journal.I flere år har Express Scripts været stolte over, at have en simpel f..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/Danske: Tre vigtige døgn venter aktiemarkederne
2
Trumps skattereform koster dyrt - citat
3
Aktier/tendens: Positive takter i regnskabsstorm og venten på Trump
4
Aktier/åbning: Novozymes spurter frem og trækker eliteindeks med sig
5
Novozymes leverer højere vækst end ventet fra årets start

Relaterede aktiekurser

Zealand Pharma A/S 124,00 0,0% Aktiekurs uændret
Zealand Pharma AS DKK1 18,00 4,0% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. april 2017 05:26:17
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170403.1 - EUROWEB7 - 2017-04-27 05:26:17 - 2017-04-27 05:26:17 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x